华润双鹤：子公司奥卡西平片获得药品注册证书

Core Viewpoint - China Resources Double Crane announced that its subsidiary, Xiangzhong Pharmaceutical, received the drug registration certificate for Oxcarbazepine Tablets from the National Medical Products Administration, indicating a significant milestone in the company's product development pipeline [1] Group 1: Product Development - The drug is intended for the treatment of primary generalized tonic-clonic seizures and partial seizures in adults and children aged 5 years and older [1] - Xiangzhong Pharmaceutical initiated the research and development of Oxcarbazepine in August 2021 and submitted the application for marketing authorization on July 26, 2024 [1] - The drug was approved for market launch on November 12, 2025, following a cumulative R&D investment of 14.2164 million yuan [1]